Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.
about
High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis.Emerging mass spectrometry-based approaches to probe protein-receptor interactions: focus on overcoming physiological barriersMass spectrometry-guided optimization and characterization of a biologically active transferrin-lysozyme model drug conjugate.Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections.Sequential antimicrobial treatment with linezolid for neurosurgical infections: efficacy, safety and cost study.
P2860
Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.
@en
Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.
@nl
type
label
Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.
@en
Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.
@nl
prefLabel
Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.
@en
Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.
@nl
P2093
P2860
P356
P1476
Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.
@en
P2093
Angela M Urmanski
Carolyn J Johnston
William J Peppard
P2860
P356
10.1586/14787210.6.1.83
P577
2008-02-01T00:00:00Z